News

Published on 20 Apr 2022 on Entrpreneur

5 Outperforming Biotech Stocks with More Room to Run

Article preview image

Thanks to the global COVID-19 vaccination drive and inelastic demand for healthcare, biotechnology stocks have been outperforming the broader markets so...

Read the rest of the article
NASDAQ.JAZZ price evolution
LSE.WISE price evolution
NASDAQ.EXEL price evolution
NASDAQ.INCY price evolution
NASDAQ.ALKS price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Incyte Gears Up to Report Q4 Earnings: Here's What You Should Know

Incyte Corporation INCY is scheduled to report fourth-quarter and full-year 2024 results on Feb. ...

Zacks · via Yahoo Finance 5 Feb 2025
Incyte's SWOT analysis: pipeline progress faces patent cliff pressure By...

Incyte's SWOT analysis: pipeline progress faces patent cliff pressure

Investing.com 26 Nov 2024
Incyte shares target lifted, buy rating on povorcitinib sales outlook By...

On Monday, Incyte (NASDAQ:INCY) Corporation (NASDAQ:INCY) shares received a positive assessment f...

Investing.com 25 Nov 2024
Goldman Sachs: Incyte Corporation (INCY) Is A Top Growth Investor Stock

We recently made a list of Goldman Sachs’ Top Growth Investors: 34 Stocks With The Highest...

Insider Monkey · via Yahoo Finance 22 Nov 2024
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.28% By...

U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.28%

Investing.com 20 Nov 2024
BMO keeps Incyte stock at underperform, price target at $52 By Investing.com

On Tuesday, BMO Capital maintained its Underperform rating for Incyte (NASDAQ:INCY) Corporation...

Investing.com 19 Nov 2024
Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two...

On Monday, Incyte Corporation (NASDAQ:INCY) announced that it will pause enrollment in the ongoin...

Benzinga · via AOL 19 Nov 2024
Nasdaq Gains 100 Points; Lowe's Earnings Beat Views - Lowe's Companies...

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining by around 100 ...

Benzinga 19 Nov 2024
Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two...

On Monday, Incyte Corporation (NASDAQ:INCY) announced that it will pause enrollment in the ongoin...

Benzinga · via Yahoo Finance 19 Nov 2024
Incyte Faces Challenges but Remains Focused on Strategic Growth

Incyte Corporation (NASDAQ:INCY) shares plunged 11.26% on Tuesday and here are some significant...

GuruFocus.com · via Yahoo Finance 19 Nov 2024

Copyright Statfolio @ 2025

Social Accounts